RheumaGen, Inc. secured $15 million in a Series A funding round co-led by SPRIM Global Investments and William Taylor Nominees to advance a Phase I clinical trial for their gene-editing therapy for rheumatoid arthritis.

Jan 09, 2025•11 months ago

Amount Raised

$15 Million

Round Type

series a

DenverBiotechnology

Investors

William Taylor NomineesSprim Global Investments

Description

RheumaGen, Inc. has announced the close of a $15 million Series A financing to support its novel HLA gene-editing therapies aimed at major autoimmune diseases. The funds will primarily be directed toward completing a Phase I clinical trial of RG0401 for treatment-resistant rheumatoid arthritis.

Company Information

Company

RheumaGen

Location

200 QUEBEC ST.

Denver, Colorado, United States

About

RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases. RheumaGen focuses on editing the human leukocyte antigen (HLA), or "immune gene," to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends